Effectiveness of antiviral treatment of patients with chronic hepatitis C GT 1b depending on the presence of comorbid chronic renal insufficiency

Authors

DOI:

https://doi.org/10.14739/2409-2932.2022.3.265483

Keywords:

chronic hepatitis C, viral infection, comorbidity, chronic renal insufficiency, hemodialysis, antiviral treatment

Abstract

Aim. The aim of the work was to analyze the effectiveness of antiviral therapy (3D mode) in patients with chronic hepatitis C (CHC) GT1 in clinical practice, depending on the presence of comorbid chronic renal insufficiency stage V, who receiving hemodialysis.

Materials and methods. 101 patients with CHC GT1 who received antiviral therapy (AVT) according to the scheme OBV/PTV/r + DSV ± RBV (3D-mode) during 12 weeks were included in the study. All patients with CHC were divided into two groups depending on the presence of comorbid chronic renal insufficiency (CRI): 92 patients who did not have accompanying CRI and 9 patients with comorbid CRI stage V who received program hemodialysis.

Results. The effectiveness of antiviral therapy in patients with CHC GT1 according to the OBV/PTV/r + DSV ± RBV scheme in clinical practice was high in terms of the achievement of 12 weeks sustained virologic response (SVR 12) SVR 12 (94.1 %). The frequency of achieving SVR 12 in CHC patients without concomitant CRI was 94.6 %, and with of comorbid CRI stage V (hemodialysis) – 88.9 % and had not statistically significant differences (P > 0.05). Treatment according to the 3D-mode was accompanied with stable normalization of ALT activity in 86.0 % of patients with CHC, and the frequency of it is achievement did not depend on the presence of comorbid CRI stage V (100.0 % vs. 85.2 % in patients without the specified concomitant pathology, P > 0.05).

Conclusions. The effectiveness of antiviral therapy in patients with CHC GT1 according to the OBV/PTV/r + DSV ± RBV scheme in clinical practice is high in terms of the achievement of SVR 12 (94.1 %) and does not depend in the presence of comorbid CRI stage V in the patient (94.6 % vs. 88.9 %, P > 0.05). The severity of liver fibrosis does not affect the effectiveness of AVT in patients with CHC GT1 in the presence of comorbid CRI stage V and without this comorbid condition.

Author Biographies

H. V. Venytska, Zaporizhzhia State Medical University, Ukraine

MD, Assistant of the Department of Infectious Diseases

O. V. Riabokon, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Infectious Diseases

References

Khatun, M., Ray, R., & Ray, R. B. (2021). Hepatitis C virus associated hepatocellular carcinoma. Advances in cancer research, 149, 103-142. https://doi.org/10.1016/bs.acr.2020.10.003

World Health Organization. (2019). World Hepatitis Day. https://www.who.int/campaigns/world-hepatitis-day/2019/10-messages-for-policymakers

The European Association for the Study of the Liver. (2021). Eliminating Hepatitis C. https://easlcampus.eu/webcastyoutube/eliminating-hepatitis-c

Public Health Center of the Ministry of Health of Ukraine. (2020, Januar 22). Virusni hepatyty B ta C yak zahroza hromadskomu zdoroviu [Viral hepatitis B and C as a threat to public health]. [in Ukrainian]. https://phc.org.ua/sites/default/files/users/user90/FINAL_MSF_2020_22_Januar_small.pdf

Resić, H., Sahović, V., Mesić, E., & Leto, E. (2003). Prevalencija i incidencija serokonverzije hepatitisa C u pacijenata na hemodijalizi [Prevalence and incidence of hepatitis C seroconversion in patients on hemodialysis]. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 57(1), 39-42.

Dudar, I. O., Palamar, B. I., Krasiuk, E. K., & Loboda, O. M. (2016). Orhanizatsiia medyko-profilaktychnoi dopomohy khvorym nefrolohichnoho profiliu u m. Kyievi: Problemy ta shliakhy vyrishennia [Organization nephrologic assistance in Kyiv city: problems and their solutions]. Ukrainskyi zhurnal nefrolohii ta dializu, (1), 24-31. [in Ukrainian].

Yakaryilmaz, F., Gurbuz, O. A., Guliter, S., Mert, A., Songur, Y., Karakan, T., & Keles, H. (2006). Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Renal failure, 28(8), 729-735. https://doi.org/10.1080/08860220600925602

Damola, A. B., Adeniji, J. A., & Bakarey, A. S. (2019). Hepatitis C virus seropositivity and the risk factors for transmission among blood donors in some selected centers in Lagos State, Southwest Nigeria. Journal of immunoassay & immunochemistry, 40(5), 528-539. https://doi.org/10.1080/15321819.2019.1647853

Raina, D., Rawat, N., & Pandita, A. K. (2022). Prevalence of Hepatitis B and Hepatitis C in Patients undergoing hemodialysis at a teaching hospital in Uttarakhand. Journal of family medicine and primary care, 11(4), 1348-1353. https://doi.org/10.4103/jfmpc.jfmpc_1017_21

Palamar, B. I. (2015). Hepatyty u khvorykh, yaki likuiutsia hemodializom [Hepatitis in patients treated by hemodialysis]. Ukrainskyi zhurnal nefrolohii ta dializu, (2), 55-60. [in Ukrainian].

Al Nasser, M. N., al Mugeiren, M. A., Assuhaimi, S. A., Obineche, E., Onwabalili, J., & Ramia, S. (1992). Seropositivity to hepatitis C virus in Saudi haemodialysis patients. Vox sanguinis, 62(2), 94-97. https://doi.org/10.1111/j.1423-0410.1992.tb01177.x

Ayoola, E. A., Huraib, S., Arif, M., al-Faleh, F. Z., al-Rashed, R., Ramia, S., al-Mofleh, I. A., & Abu-Aisha, H. (1991). Prevalence and significance of antibodies to hepatitis C virus among Saudi haemodialysis patients. Journal of medical virology, 35(3), 155-159. https://doi.org/10.1002/jmv.1890350303

Yamaguchi, K., Kiyokawa, H., Machida, J., Obayashi, A., Nojiri, N., Ueda, S., & Takatsuki, K. (1994). Seroepidemiology of hepatitis C virus infection in Japan and HCV infection in haemodialysis patients. FEMS microbiology reviews, 14(3), 253-258. https://doi.org/10.1111/j.1574-6976.1994.tb00096.x

Fabrizi, F., Takkouche, B., Lunghi, G., Dixit, V., Messa, P., & Martin, P. (2007). The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. Journal of viral hepatitis, 14(10), 697-703. https://doi.org/10.1111/j.1365-2893.2007.00868.x

Fabrizi, F., Messa, P., Basile, C., & Martin, P. (2010). Hepatic disorders in chronic kidney disease. Nature reviews. Nephrology, 6(7), 395-403. https://doi.org/10.1038/nrneph.2010.37

Telehin, D. Ie. (2003). Problema virusnykh hepatytiv u tsentrakh hemodializu [The problem of viral hepatitis in hemodialysis centers]. Praktychna medytsyna, 9(3), 91-97. [in Ukrainian].

Pol, S., Parlati, L., & Jadoul, M. (2019). Hepatitis C virus and the kidney. Nature reviews. Nephrology, 15(2), 73-86. https://doi.org/10.1038/s41581-018-0081-8

Al-Freah, M. A., Zeino, Z., & Heneghan, M. A. (2012). Management of hepatitis C in patients with chronic kidney disease. Current gastroenterology reports, 14(1), 78-86. https://doi.org/10.1007/s11894-011-0238-0

Wills R. J. (1990). Clinical pharmacokinetics of interferons. Clinical pharmacokinetics, 19(5), 390-399. https://doi.org/10.2165/00003088-199019050-00003

Bunchorntavakul, C., Maneerattanaporn, M., & Chavalitdhamrong, D. (2015). Management of patients with hepatitis C infection and renal disease. World journal of hepatology, 7(2), 213-225. https://doi.org/10.4254/wjh.v7.i2.213

Khatri, A., Dutta, S., Marbury, T. C., Preston, R. A., Rodrigues, L., Wang, H., Awni W., & Menon, R. M. (2017). Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment. Clinical Pharmacokinetics, 56(2), 153-163. https://doi.org/10.1007/s40262-016-0429-9

Yaraş, S., Üçbilek, E., Özdoğan, O., Ateş, F., Altıntaş, E., & Sezgin, O. (2019). Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey. The Turkish journal of gastroenterology, 30(4), 331-335. https://doi.org/10.5152/tjg.2018.18269

Pockros, P. J., Reddy, K. R., Mantry, P. S., Cohen, E., Bennett, M., Sulkowski, M. S., Bernstein D., Podsadecki T., Cohen D., Shulman N., Wang D., Khatri A., Abunimeh M., & Lawitz, E. (2015). LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study. Journal of Hepatology, 62, S257. https://doi.org/10.1016/s0168-8278(15)30147-1

Muñoz-Gómez, R., Rincón, D., Ahumada, A., Hernández, E., Devesa, M. J., Izquierdo, S., Ortiz, M., Hernández-Albujar, A., Fernández-Rodríguez, C., Calvo, M., González, R., Lozano, M., Castellano, G., & Fernández-Vázquez, I. (2017). Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. Journal of viral hepatitis, 24(6), 464-471. https://doi.org/10.1111/jvh.12664

Lawitz, E., Gane, E., Cohen, E., Vierling, J., Agarwal, K., Hassanein, T., Mantry, P. S., Pockros, P. J., Bennett, M., Kemmer, N., Morelli, G., Zha, J., Wang, D., Shulman, N. S., Cohen, D. E., & Reddy, K. R. (2018). Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. Kidney international reports, 4(2), 257-266. https://doi.org/10.1016/j.ekir.2018.10.003

Fabrizi, F., & Messa, P. (2015). Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?. Expert review of clinical pharmacology, 8(6), 785-793. https://doi.org/10.1586/17512433.2015.1086266

Poordad, F., Hezode, C., Trinh, R., Kowdley, K. V., Zeuzem, S., Agarwal, K., Shiffman, M. L., Wedemeyer, H., Berg, T., Yoshida, E. M., Forns, X., Lovell, S. S., Da Silva-Tillmann, B., Collins, C. A., Campbell, A. L., Podsadecki, T., & Bernstein, B. (2014). ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. The New England journal of medicine, 370(21), 1973-1982. https://doi.org/10.1056/NEJMoa1402869

Badri, P. S., King, J. R., Polepally, A. R., McGovern, B. H., Dutta, S., & Menon, R. M. (2016). Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clinical pharmacokinetics, 55(3), 275-295. https://doi.org/10.1007/s40262-015-0317-8

Klibanov, O. M., Gale, S. E., & Santevecchi, B. (2015). Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. The Annals of pharmacotherapy, 49(5), 566-581. https://doi.org/10.1177/1060028015570729

Downloads

Published

2022-11-15

How to Cite

1.
Venytska HV, Riabokon OV. Effectiveness of antiviral treatment of patients with chronic hepatitis C GT 1b depending on the presence of comorbid chronic renal insufficiency. Current issues in pharmacy and medicine: science and practice [Internet]. 2022Nov.15 [cited 2024Apr.18];15(3):301-6. Available from: http://pharmed.zsmu.edu.ua/article/view/265483

Issue

Vol. 15 No. 3 (2022)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.     Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)